Free Trial
→ “The crisis that’s emerging now is just the tip of the iceberg,” says Dr. Martin D. Weiss, who has made shocking and accurate predictions for 55 years (From Weiss Ratings) (Ad)tc pixel
NYSEAMERICAN:SER

Serina Therapeutics Q2 2026 Earnings Results & Report

Serina Therapeutics logo
$1.72 -0.07 (-3.91%)
Closing price 04:10 PM Eastern
Extended Trading
$1.87 +0.15 (+8.49%)
As of 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Serina Therapeutics reported Q2 2026 earnings on August 13, 2026. The company reported EPS of -$0.55.

Research:ProfileEarnings HistoryForecast

Earnings Announcement Details

Quarter
Q2 2026
Report Date
Time
After Market Closes
Conference Call
7:00 AM ET

Serina Therapeutics EPS Results

Actual EPS
-$0.55
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Serina Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Powered by Quartr

Earnings Documents

Serina Therapeutics' Q2 2026 Press ReleasePress Release
(8-K)
Serina Therapeutics' Q2 2026 Quarterly reportQuarterly report
(10-Q)

Serina Therapeutics Q2 2026 Earnings FAQ

Serina Therapeutics (NYSEAMERICAN:SER) reported earnings of -$0.55 per share for Q2 2026. The report was announced on Thursday, August 13, 2026.

Serina Therapeutics Earnings Headlines

Serina Therapeutics Streamlines Capital Structure After Preferred Elimination
October 9, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/serina-therapeutics-streamlines-capital-structure-after-preferred-elimination?utm_source=marketbeat.com&utm_medium=referral
Serina Therapeutics - Registration Is Now Open for Tribe Public's CEO Presentation and Q&A Webinar Event 'A New Approach to Advanced Parkinson's disease: Serina Discusses SER ...
September 24, 2026  |  marketscreener.comM
Financial legend: “This is bad, really bad...”
Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks.tc pixel
October 16 at 1:00 AM  |  Weiss Ratings (Ad)
Registration Is Now Open For Tribe Public’s CEO Presentation and Q&A Webinar Event "A New Approach to Advanced Parkinson’s Disease: Serina Discusses SER-252’s Clinical ...
September 23, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/registration-is-now-open-for-tribe-public-s-ceo-presentation-and-q-a-webinar-event-a-new-approach-to-advanced-parkinson-s-disease-serina-discusses-ser-252-s-clinical-progress-1036569098
Registration Is Now Open For Tribe Public's CEO Presentation and Q&A Webinar Event "A New Approach to Advanced Parkinson's Disease: Serina Discusses SER-252's Clinical Progress"
September 23, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/23/3367853/0/en/registration-is-now-open-for-tribe-public-s-ceo-presentation-and-q-a-webinar-event-a-new-approach-to-advanced-parkinson-s-disease-serina-discusses-ser-252-s-clinical-progress.html
Serina Therapeutics op H.C. Wainwright-conferentie: vooruitgang in Parkinson-programma
September 11, 2026  |  nl.investing.comhttps://nl.investing.com/news/transcripts/serina-therapeutics-op-hc-wainwrightconferentie-vooruitgang-in-parkinsonprogramma-93CH-912729
See More Serina Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Serina Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Serina Therapeutics and other key companies, straight to your email.

About Serina Therapeutics

Serina Therapeutics (NYSEAMERICAN:SER) is a clinical-stage biotechnology company developing medicines designed to provide controlled and sustained drug delivery. The company’s proprietary POZ polymer platform is intended to extend the duration of action of therapeutic compounds, potentially reducing dosing frequency and improving treatment convenience.

Serina’s lead product candidate is SER-252, also known as POZ-apomorphine, an investigational long-acting formulation of apomorphine being developed for patients with Parkinson’s disease. The company is evaluating the candidate as a potential treatment for motor complications associated with the disease, including fluctuations in symptom control.

Serina Therapeutics is headquartered in the United States and focuses primarily on advancing its pipeline through clinical development and partnerships. As a development-stage company, its products remain investigational and are subject to clinical, regulatory, and commercial uncertainties.

View Serina Therapeutics Profile
Earnings Tools